

Press Release
April 11, 2023



FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing

- *Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses*
- *Manufactured to cGMP-compliant standards to support production of recombinant proteins, monoclonal antibodies, and biosimilars*

SANTA ANA, California, April 11, 2023 – FUJIFILM Irvine Scientific, Inc., a global leader in the innovation and manufacture of cell culture solutions for Life Science and Medical markets, today announced the expansion of its BalanCD CHO Media Platform portfolio with the addition of two new, chemically defined growth media- BalanCD CHO Perfusion and BalanCD CHO DG44. FUJIFILM Irvine Scientific's BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of Chinese Hamster Ovary (CHO) cell lines via a scalable platform for reliable production and seamless workflow through all stages of development and manufacture, from small-scale shake flasks to large bioreactors. These new additions extend the platform with specific media designed to support DG44 cell lines and perfusion culture platforms for the commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and other biomolecule-based biotherapeutics.

BalanCD CHO Perfusion medium is a chemically defined, animal component-free medium optimized to deliver robust cell growth and productivity in steady-state, perfusion CHO culture. The medium is verified to meet industry performance standards for perfusion culture conditions including: volumetric productivity (VP); cell specific perfusion rates (CSPR); and vessel volumes per day (VVD). BalanCD CHO Perfusion is a complete and ready-to-use medium that is adaptable and scalable for a variety of perfusion culture platforms, including perfusion mimic and perfusion-capable bioreactors.

Designed for high cell density conditions and to deliver high titers, BalanCD CHO DG44 medium is specifically developed for optimal growth and productivity of CHO DG44 cell lines, one of the leading cell lines utilized for therapeutic biomolecule development and manufacture. Chemically defined, animal component-free, BalanCD CHO DG44 supports both batch and fed-batch cultures. It is compatible with a wide range of culture platforms and transfection reagents.

Erik Vaessen, chief business officer, FUJIFILM Irvine Scientific, said: "With CHO cells being such a pivotal part of many biotherapeutic development and manufacture pipelines, FUJIFILM Irvine Scientific

designed the BalanCD CHO platform to deliver consistent, high-quality growth of CHO cells and production of biomolecules to accelerate the development and manufacture of life-saving therapies for patients around the world and achieve more cost-efficiencies within biotherapeutic manufacturing.”

For more information about FUJIFILM Irvine Scientific’s BalanCD CHO platform portfolio, please visit:

<https://www.irvinesci.com/bioproduction>

ENDS

Notes to Editors





For a high-resolution image please contact Zyme Communications.

About FUJIFILM

FUJIFILM Irvine Scientific

FUJIFILM Irvine Scientific, Inc. is a global leader in the innovation and manufacture of cell culture solutions for Life Science and Medical markets, providing products and services that assist our customers in advancing healthcare initiatives. Working across discovery research, cell and gene therapy, reproductive medicine and cytogenetics, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers, manufacturers, and clinicians. For over 50 years, our Mission has been to set the standard for excellence in our products and custom solutions to enable our customers to advance healthcare. Our facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

For more information, please visit: www.irvinesci.com.

FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm's Sustainable Value Plan 2030, [click here](#). For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion \$USD at an exchange rate of 122 yen/dollar).

For more information, please visit: www.fujifilmholdings.com.

Media Contacts

Lori Serles
FUJIFILM Irvine Scientific
Phone: (949) 261-7800
Email: lori.serles@fujifilm.com

Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please [click here](#).